The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Notice for tislelizumab (Beigene Aus Pty Ltd)
Active ingredients
tislelizumab
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Concentrated injection
Indication
Treatment of nasopharyngeal carcinoma
Therapeutic area
Oncology